Form 8-K - Current report:
SEC Accession No. 0001564590-20-033048
Filing Date
2020-07-22
Accepted
2020-07-22 16:10:29
Documents
4
Period of Report
2020-07-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K abio-8k_20200722.htm 8-K 43711
2 EX-5.1 abio-ex51_7.htm EX-5.1 15563
3 EX-10.1 abio-ex101_21.htm EX-10.1 256241
4 GRAPHIC gcnp5dk0znqr000001.jpg GRAPHIC 28720
  Complete submission text file 0001564590-20-033048.txt   356673
Mailing Address 11080 CIRCLEPOINT ROAD SUITE 140 WESTMINSTER CO 80020
Business Address 11080 CIRCLEPOINT ROAD SUITE 140 WESTMINSTER CO 80020 720-940-2200
ARCA biopharma, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-22873 | Film No.: 201041606
SIC: 2835 In Vitro & In Vivo Diagnostic Substances